Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Saniona
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05147415CT.gov Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) | — | Withdrawn | — | — | — |
NCT03845075CT.gov 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acquired Hypothalamic Obesity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Beatrolol (this asset) | Saniona | P2 | B · 56 |
| Exenatide | University Hospital, Bordeaux | P3 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Novartis | P4 | BB |
| Tirzepatide | Grace Kim | P4 | BB |
| Setmelanotide | Rhythm Pharmaceuticals, Inc. | P3 | BB |
| Oxytocin | Shana McCormack, MD | P2 | B |
| Metformin | The Hospital for Sick Children | P2 | B |
| lb54640 | Rhythm Pharmaceuticals, Inc. | P2 | B |
| Tesofensine | Saniona | P2 | B |
+6 more in the Acquired Hypothalamic Obesity cohort
Other indications for Beatrolol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Heart Disorder | — | P3 | B · 60 |
| Cardiomyopathy | — | P3 | B · 60 |
| Beta Thalassemia | — | P2/3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- ExenatideUniversity Hospital, BordeauxBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-NovartisBB
- TirzepatideGrace KimBB
- SetmelanotideRhythm Pharmaceuticals, Inc.BB
- OxytocinShana McCormack, MDB
Citation
Floatz Terminal. Beatrolol in Acquired Hypothalamic Obesity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/beatrolol-acquired-hypothalamic-obesity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →